Dingwei Ye

2.6k total citations
88 papers, 1.2k citations indexed

About

Dingwei Ye is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Dingwei Ye has authored 88 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Pulmonary and Respiratory Medicine, 35 papers in Surgery and 32 papers in Oncology. Recurrent topics in Dingwei Ye's work include Renal cell carcinoma treatment (28 papers), Bladder and Urothelial Cancer Treatments (26 papers) and Prostate Cancer Treatment and Research (25 papers). Dingwei Ye is often cited by papers focused on Renal cell carcinoma treatment (28 papers), Bladder and Urothelial Cancer Treatments (26 papers) and Prostate Cancer Treatment and Research (25 papers). Dingwei Ye collaborates with scholars based in China, United States and United Kingdom. Dingwei Ye's co-authors include Yao Zhu, Bo Dai, John Mendelsohn, Zhen Fan, Guohai Shi, Hailiang Zhang, Yuanyuan Qu, Kun Chang, Weijie Gu and Jie Jin and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Dingwei Ye

80 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Dingwei Ye China 17 621 502 417 303 286 88 1.2k
Xianshu Gao China 18 477 0.8× 314 0.6× 520 1.2× 242 0.8× 292 1.0× 95 1.2k
Sylvie Job France 17 493 0.8× 434 0.9× 417 1.0× 376 1.2× 457 1.6× 23 1.1k
Tyler P. Robin United States 17 405 0.7× 330 0.7× 608 1.5× 272 0.9× 198 0.7× 55 1.3k
Tomoyoshi Takayama Japan 16 462 0.7× 401 0.8× 464 1.1× 401 1.3× 180 0.6× 43 1.2k
Alessia Mennitto Italy 19 479 0.8× 271 0.5× 549 1.3× 212 0.7× 225 0.8× 59 1.0k
Teodoro Sava Italy 18 554 0.9× 292 0.6× 502 1.2× 282 0.9× 231 0.8× 69 1.1k
Arash Rezazadeh Kalebasty United States 14 531 0.9× 364 0.7× 630 1.5× 442 1.5× 164 0.6× 69 1.2k
Caroline E. McCoach United States 18 1.0k 1.7× 413 0.8× 757 1.8× 290 1.0× 383 1.3× 56 1.5k
Javier Puente Spain 18 639 1.0× 424 0.8× 786 1.9× 320 1.1× 426 1.5× 164 1.5k

Countries citing papers authored by Dingwei Ye

Since Specialization
Citations

This map shows the geographic impact of Dingwei Ye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dingwei Ye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dingwei Ye more than expected).

Fields of papers citing papers by Dingwei Ye

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dingwei Ye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dingwei Ye. The network helps show where Dingwei Ye may publish in the future.

Co-authorship network of co-authors of Dingwei Ye

This figure shows the co-authorship network connecting the top 25 collaborators of Dingwei Ye. A scholar is included among the top collaborators of Dingwei Ye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dingwei Ye. Dingwei Ye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Zhongyuan, Aihetaimujiang Anwaier, Xi Tian, et al.. (2025). Spatially segregated APOE+ macrophages restrict immunotherapy efficacy in clear cell renal cell carcinoma. Theranostics. 15(11). 5312–5336. 2 indexed citations
2.
Cai, Tingting, Tao Feng, Wei Zhang, et al.. (2025). Neutrophil extracellular traps–STC1 positive feedback loop promotes immune evasion and metastasis in bladder cancer. Journal for ImmunoTherapy of Cancer. 13(11). e012736–e012736.
3.
Galsky, Matthew D., John P. Sfakianos, Dingwei Ye, et al.. (2025). Phase II study of oral APL-1202 plus tislelizumab or tislelizumab alone as neoadjuvant therapy in patients with muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology. 43(5_suppl). 793–793. 1 indexed citations
4.
5.
6.
Lü, Xiaolin, Li‐Ping Ge, Zhaopei Liu, et al.. (2024). CXCR6 expression predicts prognosis and immunotherapeutic benefit in muscle-invasive bladder cancer. Frontiers in Oncology. 14. 1498579–1498579. 1 indexed citations
7.
Wang, Yichen, Yanyang Nan, Chunguang Ma, et al.. (2024). A potential strategy for bladder cancer treatment: inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE. Cell Death and Disease. 15(4). 293–293. 9 indexed citations
8.
Anwaier, Aihetaimujiang, Jianhui Chen, Xinxin Zhao, et al.. (2022). Real-world data on the efficacy and safety of pazopanib in IMDC favorable- and intermediate-risk metastatic renal cell carcinoma: a multicenter retrospective cohort study of Chinese patients. Translational Andrology and Urology. 11(5). 694–709. 3 indexed citations
9.
Xu, Wenhao, Aihetaimujiang Anwaier, Chunguang Ma, et al.. (2021). Prognostic Immunophenotyping Clusters of Clear Cell Renal Cell Carcinoma Defined by the Unique Tumor Immune Microenvironment. Frontiers in Cell and Developmental Biology. 9. 785410–785410. 17 indexed citations
10.
11.
Mengual, Lourdes, Bin Kang, Juan José Lozano, et al.. (2018). Validation of Urine-based Gene Classifiers for Detecting Bladder Cancer in a Chinese Study. Journal of Cancer. 9(17). 3208–3215.
12.
Ma, Jian, Kun Chang, Jingtao Peng, et al.. (2018). SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression. Journal of Experimental & Clinical Cancer Research. 37(1). 145–145. 46 indexed citations
13.
Gross‐Goupil, Marine, Tae‐Geon Kwon, Masatoshi Eto, et al.. (2018). Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Annals of Oncology. 29(12). 2371–2378. 176 indexed citations
14.
Gu, Weijie, Yao Zhu, & Dingwei Ye. (2017). Beyond chemotherapy for advanced disease—the role of EGFR and PD-1 inhibitors. Translational Andrology and Urology. 6(5). 848–854. 13 indexed citations
15.
Dai, Bo, Kun Chang, Yunyi Kong, et al.. (2015). [Analysis of biochemical recurrence following radical prostatectomy].. PubMed. 53(4). 261–5. 1 indexed citations
16.
Qu, Yuanyuan, Bo Dai, Dingwei Ye, et al.. (2015). Constitutively Active AR-V7 Plays an Essential Role in the Development and Progression of Castration-Resistant Prostate Cancer. Scientific Reports. 5(1). 7654–7654. 125 indexed citations
17.
Gu, Weijie, Yao Zhu, Xudong Yao, et al.. (2014). The effects of marital status on prognosis of patients with squamous cell carcinoma of the penis. 28(2). 19–22. 1 indexed citations
18.
Shi, Guohai, Dingwei Ye, Xudong Yao, et al.. (2011). Clinical efficacy and tolerance of sunitinib in the treatment of advanced renal cell carcinoma. Zhonghua miniao waike zazhi. 32(6). 423–426. 1 indexed citations
19.
Zhang, Hailiang, Dingwei Ye, Xudong Yao, et al.. (2008). Role of KIT expression in the prognosis of clear cell renal cell carcinomas in Chinese patients. Journal of Cancer Research and Clinical Oncology. 135(2). 249–253. 7 indexed citations
20.
Ye, Dingwei, et al.. (1993). Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors. Urological Research. 21(1). 39–43. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Xianshu Gao Breakdown of academic impact, for papers by Sylvie Job Breakdown of academic impact, for papers by Tyler P. Robin Breakdown of academic impact, for papers by Tomoyoshi Takayama Breakdown of academic impact, for papers by Alessia Mennitto Breakdown of academic impact, for papers by Teodoro Sava Breakdown of academic impact, for papers by Arash Rezazadeh Kalebasty Breakdown of academic impact, for papers by Caroline E. McCoach Breakdown of academic impact, for papers by Javier Puente
Rankless by CCL
2026